Sanofi and Regeneron Biologic Drug Dupixent Notches a New …
WEB2 hours ago · The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB2 days ago · Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA) and Regeneron's (REGN.O) blockbuster drug Dupixent for patients with a chronic lung disease, commonly known...
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEB2 days ago · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB2 days ago · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB2 days ago · The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung disease. The decision could significantly expand use of what is already one of the industry’s best-selling medicines.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB2 days ago · Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD. Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils. Wikimedia Commons. By...
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic
WEB2 days ago · (RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved Dupixent as an add-on maintenance treatment of adults...
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
WEB2 days ago · Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Regeneron and Sanofi Provide Update on Dupixent® …
WEBOct 20, 2023 · Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
Sanofi US News
WEBMay 20, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.
Skip to content